Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being studied in patients
Source: medindia.net